To further investigate the mechanism underlying tumor growth inhibition by FAP/IL-15 CAR-T cell therapy, xenograft models using HepG2-hFAP, U87, and primary hepatic carcinoma cells were established (Fig. 4A). This evidence concerns the gene IL15 and hepatocellular carcinoma.